- Home
- MNTK vs ERAS Comparison
MNTK vs ERAS Comparison
Compare MNTK & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- ERAS
- Stock Information
- Founded
- MNTK 1980
- ERAS 2018
- Country
- MNTK United States
- ERAS United States
- Employees
- MNTK N/A
- ERAS N/A
- Industry
- MNTK Natural Gas Distribution
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- ERAS Health Care
- Exchange
- MNTK Nasdaq
- ERAS Nasdaq
- Market Cap
- MNTK 798.5M
- ERAS 719.0M
- IPO Year
- MNTK 2021
- ERAS 2021
- Fundamental
- Price
- MNTK $4.12
- ERAS $2.67
- Analyst Decision
- MNTK Hold
- ERAS Strong Buy
- Analyst Count
- MNTK 2
- ERAS 5
- Target Price
- MNTK $6.00
- ERAS $6.10
- AVG Volume (30 Days)
- MNTK 214.6K
- ERAS 1.7M
- Earning Date
- MNTK 11-12-2024
- ERAS 11-12-2024
- Dividend Yield
- MNTK N/A
- ERAS N/A
- EPS Growth
- MNTK 42.11
- ERAS N/A
- EPS
- MNTK 0.16
- ERAS N/A
- Revenue
- MNTK $194,849,000.00
- ERAS N/A
- Revenue This Year
- MNTK $22.46
- ERAS N/A
- Revenue Next Year
- MNTK $22.06
- ERAS N/A
- P/E Ratio
- MNTK $25.47
- ERAS N/A
- Revenue Growth
- MNTK 9.63
- ERAS N/A
- 52 Week Low
- MNTK $3.38
- ERAS $1.51
- 52 Week High
- MNTK $9.75
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- MNTK 29.06
- ERAS 43.56
- Support Level
- MNTK $4.00
- ERAS $2.59
- Resistance Level
- MNTK $5.78
- ERAS $3.19
- Average True Range (ATR)
- MNTK 0.42
- ERAS 0.20
- MACD
- MNTK -0.20
- ERAS -0.02
- Stochastic Oscillator
- MNTK 5.88
- ERAS 20.13
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a United States-based renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments: Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.